Extracted from this filing and checked against the source text.
Shareholder VotesSEC 8-K Item 5.07confidence 0.9
Inmune Bio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.
Proposal
director election
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Proposal One: Election of Directors. Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company’s stockholders and until his or her successor is elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes David Moss 6,834,995 2,120,682 8,501,317 J. Kelly Ganjei 5,955,609 3,000,068 8,501,317 Tim Schroeder 6,622,916 2,332,761 8,501,317 Scott Juda, JD 7,508,310 1,447,367 8,501,317 Marcia Allen 6,342,910 2,612,767 8,501,317 1
Inmune Bio, Inc. shareholders approved Ratification of Appointment of Independent Auditor at the 2026-06-16 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Proposal Two: Ratification of Appointment of Independent Auditor. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2026. For Against Abstentions Broker Non-Votes 17,293,255 107,064 56,675 0
Inmune Bio, Inc. shareholders approved Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan at the 2026-06-16 meeting.
Proposal
equity plan
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Proposal Three: Approval of the Third Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan. As noted above, the stockholders approved the Amended Plan. For Against Abstentions Broker Non-Votes 6,085,086 2,775,224 95,367 8,501,317
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.